Wealthfront Advisers’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.1M | Sell |
45,019
-504
| -1% | -$12.3K | ﹤0.01% | 663 |
|
|
2025
Q1 | $945K | Buy |
45,523
+2,277
| +5% | +$47.3K | ﹤0.01% | 672 |
|
|
2024
Q4 | $1.02M | Sell |
43,246
-7
| -0% | -$165 | ﹤0.01% | 658 |
|
|
2024
Q3 | $1.11M | Sell |
43,253
-1,305
| -3% | -$33.4K | ﹤0.01% | 627 |
|
|
2024
Q2 | $1.05M | Sell |
44,558
-19,767
| -31% | -$464K | ﹤0.01% | 611 |
|
|
2024
Q1 | $1.85M | Buy |
64,325
+19,611
| +44% | +$564K | 0.01% | 498 |
|
|
2023
Q4 | $1.47M | Buy |
44,714
+4,089
| +10% | +$134K | 0.01% | 523 |
|
|
2023
Q3 | $1.13M | Buy |
40,625
+8,180
| +25% | +$228K | ﹤0.01% | 529 |
|
|
2023
Q2 | $1.11M | Sell |
32,445
-3,973
| -11% | -$135K | ﹤0.01% | 535 |
|
|
2023
Q1 | $1.1M | Buy |
36,418
+2,951
| +9% | +$88.7K | 0.01% | 510 |
|
|
2022
Q4 | $945K | Buy |
33,467
+2,453
| +8% | +$69.2K | ﹤0.01% | 522 |
|
|
2022
Q3 | $1.02M | Sell |
31,014
-2,209
| -7% | -$72.6K | 0.01% | 481 |
|
|
2022
Q2 | $1.05M | Buy |
33,223
+2,163
| +7% | +$68.1K | 0.01% | 483 |
|
|
2022
Q1 | $1.43M | Buy |
31,060
+7,783
| +33% | +$358K | 0.01% | 468 |
|
|
2021
Q4 | $1.43M | Buy |
23,277
+8,609
| +59% | +$527K | 0.01% | 447 |
|
|
2021
Q3 | $1.1M | Buy |
+14,668
| New | +$1.1M | 0.01% | 458 |
|